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Background: The Mental Health Biomarker Project (2010–2014) selected commercial biochemistry markers related
to monoamine synthesis and metabolism and measures of visual and auditory processing performance. Within a
case–control discovery design with exclusion criteria designed to produce a highly characterised sample, results
from 67 independently DSM IV-R-diagnosed cases of schizophrenia and schizoaffective disorder were compared
with those from 67 control participants selected from a local hospital, clinic and community catchment area.
Participants underwent protocol-based diagnostic-checking, functional-rating, biological sample-collection for thirty
candidate markers and sensory-processing assessment.
Results: Fifteen biomarkers were identified on ROC analysis. Using these biomarkers, odds ratios, adjusted for a
case–control design, indicated that schizophrenia and schizoaffective disorder were highly associated with dichotic
listening disorder, delayed visual processing, low visual span, delayed auditory speed of processing, low reverse
digit span as a measure of auditory working memory and elevated levels of catecholamines. Other nutritional and
biochemical biomarkers were identified as elevated hydroxyl pyrroline-2-one as a marker of oxidative stress, vitamin
D, B6 and folate deficits with elevation of serum B12 and free serum copper to zinc ratio.
When individual biomarkers were ranked by odds ratio and correlated with clinical severity, five functional domains
of visual processing, auditory processing, oxidative stress, catecholamines and nutritional-biochemical variables were
formed. When the strengths of their inter-domain relationships were predicted by Lowess (non-parametric) regression,
predominant bidirectional relationships were found between visual processing and catecholamine domains. At a
cellular level, the nutritional-biochemical domain exerted a pervasive influence on the auditory domain as well as on all
other domains.
Conclusions: The findings of this biomarker research point towards a much-required advance in Psychiatry:
quantification of some theoretically-understandable, translationally-informative, treatment-relevant underpinnings of
serious mental illness. This evidence reveals schizophrenia and schizoaffective disorder in a somewhat different manner,
as a conglomerate of several disorders many of which are not currently being assessed-for or treated in clinical
settings. Currently available remediation techniques for these underlying conditions have potential to reduce
treatment-resistance, relapse-prevention, cost burden and social stigma in these conditions. If replicated and validated
in prospective trials, such findings will improve progress-monitoring and treatment-response for schizophrenia and
schizoaffective disorder.
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The architecture of schizophrenia is still largely unknown
and conventional systems for diagnosing schizophrenia
and schizo-affective states are still based on phenome-
nological descriptions of symptoms and behaviours [1].
While progress has been made regarding the underlying
molecular biology and neuropathology of schizophrenia,
its characterization has not improved beyond coarse div-
ision of its symptoms into “positive” and “negative” types
that may not truly reflect underlying neurobiological
mechanisms [2]. Finding biomarkers, directly linked to the
underlying structure of schizophrenia, could be a great
leap forward for Psychiatry so the search for peripheral
and central markers for these serious mental illness
conditions and for affective disorders has been under-
way for many years [3]. Many uni-dimensional studies
have tested specific biomarkers based on the hypotheses
of monoamine, neuro-immune-inflammatory, neuroen-
docrine and neuroplasticity dysfunction [4]. Other studies
have tested the ability of multi-analyte technology to
profile biomarkers. These techniques have the capacity to
generate thousands of markers that may demonstrate
overall predictive power but yield only marginal under-
standing of the disease process and no causal framework
for practical application to assessment and treatment in
the clinical context [5].
Against this background of heterogeneity, overlapping
co-morbidity and fading faith in the validity of descrip-
tive classification systems [6], schizophrenia and related
psychotic conditions are increasingly viewed as complex,
polygenic diseases involving hundreds of forms of func-
tional pathology. For this reason, investigation of puta-
tive biomarkers across a number of functional domains,
may better reflect heterogeneity and assist to identify
sub-phenotypic areas within the schizophrenia condition.
Moreover, in the clinical setting, insufficient presenting
symptoms that fail to meet criteria for any firm diagnosis,
cause primary-care clinicians considerable stress. They
must walk a fine line between knowing that the earlier
schizophrenia is diagnosed and treatment begun, the
better the outcome may be [7] and knowing that un-
necessary cost and distress may accompany an inaccurate
diagnosis [8]. For both reasons quantitative confirmation
of the underlying causal components of serious mental ill-
ness is urgently required, in order to augment professional
judgement about accuracy of diagnosis and clinical man-
agement of the presenting condition [9].
Schizophrenia and schizoaffective disorder are allied
conditions within the clinical setting. DSM IV-TR classi-
fication system describes schizoaffective disorder as a
major mood disorder episode occurring concurrent with
symptoms that meet characteristic symptoms for schi-
zophrenia [10]. The Mental Health Biomarker Project
(2010–2014) sought to investigate candidate markers witha high possibility of being associated with schizophrenia
or schizo-affective disorder aetiology, across a number
of putative functional domains. These domains included
neurotransmitter synthesis and metabolism, oxidative
stress, nutrition (vitamin and mineral enzyme co-factors),
visual and auditory information processing. This project’s
inquiry in the biochemical domain has a theoretical basis
explained by remote and proximal pathways related to
monoamine synthesis and metabolism and an overview of
this biochemistry landscape is depicted in Figure 1. In
undertaking this research, we considered it important to
use accessible, commercially-available laboratory tests,
easily-procurable inexpensive equipment and simple-
to-use assessment methods that could be conducted in a
45 minute low ambient noise clinic consultation.
Results
Patient characteristics
In this retrospective case–control study, 67, DSM-IV-R
diagnosed [11] participants, between 18 and 60 years of
age were enrolled from the western catchment area of
Adelaide, South Australia. In order to exclude as many
confounding variables as possible, participants were
subject to multiple selection exclusion criteria as out-
lined in the Methods section. A small data set was
therefore obtained and data analysis was carried out on
hundred and thirty four participants (67 cases and 67
controls). The sample was analysed as total cases versus
total controls and no separate analysis by age and sex
was conducted due to sample size. Baseline case–control
sample characteristics for age and sex, BMI, urine
creatinine, near vision, auditory thresholds and in
Table 1.
Candidate marker results
Figure 1 depicts the relationship between candidate
markers for which results are given. These candidate
markers exist in biochemical pathways which have poten-
tial to exert subtle, yet cumulative effects on catechol-
amine neurotransmitter synthesis and metabolism via
deficits or excesses in enzyme cofactors and intermediate
substances related to folate and methionine (one-carbon)
cycles [12-14]. Results related to catecholamines were for
urine dopamine, noradrenaline, adrenaline, homovanillic
acid (HVA), methoxy-hydroxymandelic acid (MHMA),
5-hydroxyindoleacetic acid (5-HIAA) [15], creatinine and
hydroxyhemopyrroline-2-one (HPL) - a metabolite indi-
cative of oxidative stress [16]. Results related to vitamins
and mineral enzyme cofactors and intermediate sub-
stances were for vitamin D [17], these vitamin B6, B12
[18,19], folate [20], copper and red cell zinc [21,22], homo-
cysteine [23], ceruloplasmin [24], histamine [25], and
methyltetrahydrofolate reductase (MTHFR 677 C- > T)
gene polymorphism [26]. Participants were also given a
Figure 1 Cofactor vitamins and minerals in relationship to catecholamine biochemistry. DOPA – dihydroxyphenylalanine, BH4 - tetrahydrobiopterin
BH2 – dihydrobiopterin, MTHFR- Methylenetetrahydrofolate reductase, MAT - Methionine adenosyltransferase, SAMe - S-Adenosylmethionine,
MT - Methyltransferase, SAH- S-Adenosylhomocysteine, SAHH - S-Adenosylhomocysteine-hydrolase, CBS - Cystathione Beta Synthetase,
BHMT - Betainehomocysteine methyltrasferase, DMG - Dimethylglycine, TMG - Trimethylglycine, MSR - Methionine sulphoxide reductase,
MS - Methionine synthase, 5HIAA – 5-hydroxyondolacetic acid, HVA – homovanillic acid, MAO- monoamineoxidase., MHMA - 3-methoxy-
4-hydroxymandelic acid = VMA-Vanillylmandelic acid, FAD - flavin adenine dinucleotide, MHPG -4-hydroxy-3-methoxyphenylglycol,
DOPAL – dihydroxyphenylacetaldehyde, DOPAC - dihydroxyphenylacetic acid, DOPEGAL – dihydroxyphenylglycolaldehyde,
DOMA – dihydroxymandelic acid DHPG – dihydroxyphenylglycal, COMT- catechol-o-methyl-transferase.
Table 1 Baseline characteristics of case and control groups (n 67)
Parameter Number patients Mean patients Standard error Number controls Mean controls Standard error
Age participants 67 40.5 1.3 67 45.7 1.4
Age males 37 38.6 1.4 33 46.4 1.7
Age females 30 42.9 2.4 34 45.0 2.2
Body mass index (BMI) 53 30.0 1.2 66 26.7 0.6
Right hand dominance % 65 92.6 2.1 67 93.1 1.7
Urine creatinine (mmol/L) 66 9.2 0.7 67 9.5 0.7
% hydroxyl indole acetic
acid (5-HIAA)
66 4.3 0.8 67 1.6 0.1
Plasma homocysteine (umol/L) 66 10.0 0.3 66 9.5 0.3
Red cell acetylcholine
esterase (U/gb Hb)
61 39.8 0.7 67 39.6 0.7
Hearing threshold (Db) 60 533.3 33.3 64 515.6 24.8
Visual threshold of near vision 61 6.3 0.5 67 5.2 0.1
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Table 2 Variables distribution summary for biomarkers
ROC variable No Obs Obs. without
missing data







Visual span 134 126 0.00 8.00 5.476 1.35 6.00 1.00 Pert
Visual speed of processing
discrepancy (% of age)
134 122 −90.00 207.69 6.01 54.44 −5.55 30.24 Log Normal
Distance vision on right 134 128 0.00 36.00 7.98 6.03 6.00 1.50 Chi-square
Auditory domain
Reverse digit span 134 127 2.00 8.00 4.22 1.33 4.00 1.00 Gamma (3P)
Competing words
discrepancy
(% of pass score)




134 121 −100.00 220.00 −3.83 56.68 −18.00 31.12 Gen. Extreme
Value
Catecholamine domain
Dopamine 134 133 45.00 358.00 142.47 53.64 129.0 32.00 Log-Logistic
Noradrenaline 134 133 3.00 106.00 25.278 18.53 19.00 9.00 Johnson SB
Adrenaline 134 133 0.00 27.00 4.413 5.10 2.00 1.00 Log-Logistic
HPL/Creatinine model 134 133 0.35 40.04 4.586 5.94 2.47 1.18 Burr
Nutrition-Biochemistry domain
Free copper to Zinc ratio 134 133 −1.85 1.60 0.267 0.52 0.31 0.31 Log-Logistic
B6 activation 134 129 12.80 1570.0 140.44 164.6 90.00 25.00 Gen. Extreme
Value
Red cell folate 134 133 506.00 3291.0 1788.9 448.7 1733. 236.00 Log-Logistic
Serum B12 134 134 42.00 1388.0 406.15 178.5 367.0 104.00 Gen. Extreme
Value
Vitamin D 134 132 13.00 149.00 52.462 22.15 52.00 14.00 Dagum
Fryar-Williams and Strobel Biomarker Research  (2015) 3:3 Page 4 of 21number of auditory and visual assessments for distance
vision, visual span, competing words (dichotic listening),
reverse digit span (working memory) and visual and
auditory speed of processing (as a percent of age).
ROC analysis
Receiver Operating Curve (ROC) variables [27,28], were
analysed using XLSTAT software [29], however many of
these variables lacked normal distribution and their
characteristics, as determined by EasyFit software [30]
are outlined in Table 2.
Variables that were not successful as biomarkers on
ROC analysis were: methyltetrahydrofolate reductase
(MTHFR C667T) polymorphism, plasma homocyst-
eine and urine metabolites homovanillic acid (HVA)
and methoxy-hydroxymandelic acid (MHMA). Despite
this, the homozygous MTHFR (677 T) polymorphism dem-
onstrated a significant positive correlation with elevated
homocysteine (n 132, rho 0.223, P 0.010 for levels > 12
umol/L). The serotonin metabolite, 5-hydroxyindoleacetic
acid (HIAA), also failed to produce a sufficient areaunder the curve (AUC > 0.6). High histamine produced
a poor quality ROC curve, however together with nor-
adrenaline, produced a significant ROC AUC of 0.86. In
the field of sensory-processing assessment, all putative
variables tested reached ROC-identified biomarker
status, with the exception of outcome measures for
gap-detection, auditory-figure ground tests for auditory
processing disorder and near vision on Sussex near
vision test.
Fifteen main variables emerged from ROC analysis with
an AUC of > 0.6 at the 95 percent level of significance and
one variable (for vitamin B12) with a ROC of only 0.565
contributed to the overall strength of the biochemistry
components. These variables were segregated into five
functional domains (Table 3). The first domain contains
measures of visual cognitive performance and processing
(Visual domain). The second domain contains of mea-
sures of auditory cognitive performance and processing
(Auditory domain). The third domain contains measures
of catecholamines with potential for neurotransmitter ac-
tion (Catecholamine domain). The fourth domain consists
Table 3 ROC results for schizophrenia and schizoaffective disorder, with odds ratios














Low visual span 126 0.862 22.46 < 0.0001 High Dopamine 133 0.702 9.60 <0.0001
High visual speed of processing
discrepancy (% of age)
122 0.875 27.22 < 0.0001 High Noradrenaline 133 0.851 21.25 < 0.0001
Poor distance vision on right 128 0.597 5.17 0.0001 High Adrenaline 133 0.844 14.32 < 0.0001
Visual domain 120 0.915 41.48 < 0.0001 Catecholamine domain 133 0.859 4.12 <0.0001
Reverse digit span 126 0.862 11.00 <0.0001
High competing words discrepancy
(% of pass score)
124 0.875 10.69 <0.0001 Low vitamin B6 activated 129 0.638 3.75 0.0009
High auditory speed of processing
discrepancy (% for age)
121 0.874 21.23 <0.0001 High free copper to
zinc ratio
133 0.611 2.60 0.0104
Auditory domain 119 0.891 29.57 <0.0001 Low red cell folate 133 0.654 3.64 0.0005
Low vitamin D 132 0.651 3.24 0.0026
High (HPL/Creatinine) model 133 0.696 4.12 < 0.0001 High serum B12 (80% CI) 134 0.565 1.89 0.0933
Oxidative stress domain 133 0.696 4.12 <0.0001 Nutrition-Biochemistry 126 0.797 8.5 < 0.0001
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of haeme-related oxidative stress. The fifth domain
consists vitamin and mineral cofactors for catechol-
amine synthesis and metabolism (Nutritional-biochemical
domain).
Biomarker variables within the first, visual domain are
visual (symbol) span, threshold visual speed of process-
ing performance as a percentage of age and reduced
distance-vision score on right (representing asymmetric
binocular distance-vision acuity). When pooled together
these biomarkers demonstrated strength on ROC analysis
with AUC (0.915, P < 0.0001) with domain sensitivity of
89% and specificity of 85%.
Biomarker variables in the second, auditory domain
are reverse digit span (measures verbal, auditory working
memory), competing-words performance for age as a
percentage of age (representing intra-cerebral dichotic
processing of auditory information) and threshold speed
of auditory processing as a percentage of age. When
pooled together these biomarkers demonstrated ROC
AUC (0.891, P < 0.0001) with domain sensitivity of 87%
and specificity of 82%.
Biomarker variables within the third, catecholamine do-
main are in order of strength: Noradrenaline, Adrenaline
and Dopamine. When pooled together these biomarkers
demonstrated ROC analysis AUC (0.859, P < 0.0001) with
domain sensitivity of 84% and specificity of 75%.
Within the fourth domain, hydroxyhaemopyrroline-2-one,
the sole biomarker in the HPL/creatinine domain is identi-
fied as a marker of oxidative stress. It demonstrated an
AUC of 0.696 with sensitivity of 70% and specificity of 64%.
Variables within the fifth, Nutrition domain are high
serum B12 and ratio of free copper to red cell zinc. Also
low red cell folate, activated B6 (Pyridoxal-5’-phosphatecoenzyme form) and serum vitamin D (25-OH). When
pooled together these biomarkers demonstrated ROC
analysis AUC (0.797, P < 0.0001) with domain sensitivity
of 55% and specificity of 88%.
Odds ratio of diagnostic association and Spearman’s
correlation analysis
Odds Ratio analysis may be used with ROC analysis in a
case–control study to approximate the relative risk of
particular pathological outcome measures being asso-
ciated with a low period prevalence disorder such as
schizophrenia or schizoaffective disorder [31] (Table 3).
Despite this, some statisticians claim that odds of associ-
ation results may be inflated by up to three times with a
case–control design. [32]. Despite this empirical esti-
mate, given that most ROC variables identified in our
study achieved a robust odds ratio of much over 2, all
domain odds ratios were checked for their capacity to
survive a “division by three” test and those that passed
this test fell into five domains. These are ranked below,
in descending order:
Using Spearman’s correlation analysis, discrete symptom
intensity ratings from the Brief Psychiatric Rating Scale
(BPRS) [11] and the Positive and Negative Syndrome Scale
for Schizophrenia (PANSS) [33], were summated for each
participant’s clinical or subclinical symptoms, to give an
overall Symptom Intensity Rating index (SIR). This index
was taken as measure of clinical severity and investigated
by Spearman’ correlates with respect to other ROC
variables. On Spearman’s correlation analysis, all do-
mains of interest correlated significantly with SIR at the
95 per cent level of significance and high correlations
with the clinical severity (SIR) also fell into five ranked
domains:
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(divided by three) and SIR-Spearman’s correlation
Rank I: Visual biomarkers
Odds ratio: high visual processing speed % discrepancy for
age (n 122, OR 9.07, P <0.0001), low visual span (n 126,
OR 7.46, P < 0.0001).
SIR-correlates: low visual span (n 126, rho 0.605,
P < 0.0001), delayed visual speed of processing (n 122,
rho 0.575, P <0.0001).
Rank II: Auditory biomarkers
Odds ratio: high competing words (dichotic listening)
discrepancy (n 124, OR 10.67, P < 0.0001), high audi-
tory speed of processing as a % of age (n 121, OR 7.08,
P < 0.0001), (low reverse digit span (n 127, OR 3.7,
P < 0.0001).
SIR correlates: delayed auditory speed of processing (n
120, rho 0.570, P < 0.0001), low competing words (dichotic
listening) performance (n 124, rho 0.505, P <0.0001), (low
reverse-digit span (n 128, rho 0.384, P <0.0001).
Rank III: Elevated catecholamine biomarker domain
Odds ratio: elevated Noradrenaline (n 133, OR 7.08,
P < 0.0001), elevated Adrenaline (n 133, OR 4.77, P <
0.0001), elevated dopamine (n 133, OR 3.2, P <0.0001).
SIR correlates: high noradrenalin (n 133, rho 0.575,
P < 0.0001), high adrenaline (n 133, rho 0.455, P <0.0001),
high histamine and NA (n 126, rho 0.427, P < 0.0001).
Rank IV: HPL/Creatinine, oxidative stress domain
A significant correlative relationship also existed between
the oxidative stress marker, elevated HPL/creatinine and
SIR (n 133, rho 0.327, P < 0.0001), with correlations also
found between elevated catecholamine levels and auditory
and visual domain deficits (Table 4).
Rank V: Overall nutrition-biochemistry domain
Odds ratio: n 126, OR 2.83, P < 0.0001.
SIR correlates: (n 126, rho, 0.404, P <0.0001).
SIR was also found to correlate with specific ROC vari-
ables for high noradrenaline (n 124, rho 0.381, P <0.0001,
high adrenalin (n 124 rho 0.302, P 0.000) and high dopa-
mine (n124, rho 0.301, P 0.000).Table 4 Domain inter-correlations
Rho). ROC model (108 0bs) Visual domain Auditory domain Ca
Visual domain n 120 1 0.555 0.
Auditory domain n119 0.555 1 0.
Catecholamine domain n 133 0.448 0.481 1
HPL/Creatinine n133 0.310 0.337 0.
Nutrition domain n 126 0.294 0.384 0.
Values in bold are different from 0 with a significance level of alpha = 0.05 and rhoTranslational cross-domain relationships
On Spearman’s correlation analysis, all domains of inter-
est inter- correlated significantly at the 95 per cent level
of significance and inter-domain results are presented in
Table 4.
Ranking of biomarker strengths into five ranked
domains according to odds ratio and SIR-correlates,
revealed interesting strength-related relationships be-
tween biomarker domains. However when ROC variable
translational strengths were predicted by Lowess (non-
parametric, locally-weighted) regression analysis [34]
for which the ideal predictive probability is 60% or
more, at goodness of fit (R2) of 0.6 or better. When re-
sults were presented within the framework of the
previous five ranked domains, a similar - yet dif-
ferent view of ROC translational relationships emerged
(Figures 2 and 3).
Discussion
Obtaining these biomarkers of schizophrenia and schi-
zoaffective disorder utilises readily-procurable laboratory
tests, inexpensive equipment, and easy-to-use assessment
methods that be conducted in a 45 minute consultation,
by a health practitioner in a low ambient noise, everyday
clinical setting. Outcome measures obtained are then
ROC- analysed to define biomarkers that are then allo-
cated to one of the five domains of neuro-biological
inquiry. Together these represent aspects of schizophrenia
and schizoaffective disorder that reveal new aspects of
these conditions.
Moreover, odds ratio of diagnostic association and
Spearman’s correlation with symptom severity (SIR) indi-
cate that domains of function in schizophrenia and schi-
zoaffective disorder rank into five descending strengths.
Translational predictions from Lowess regression analysis
preserve this ranking but reveal, (as would be expected),
that the lowest-ranking nutritional-biochemical cellular
domain exerts a powerful translational influence on all
other biochemical and neurone-dependent sensory pro-
cessing domains.
Rank I: Visual domain
Reduced visual (symbol) span (a measure of visual






> 0.3 have a P value of < 0.0001.
Figure 2 Percentage translational relationships of strength-ranked biomarkers for schizophrenia and schizoaffective disorder, where
R2 = goodness of fit.
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Figure 3 Translational cross-talk between biomarker domains.
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found to achieve biomarker status. When pooled together
these biomarkers demonstrated the greatest strength on
ROC analysis. On translational analysis, processing in the
visual domain was found to be influenced by oxidative
stress (HPL) and low levels of vitamin D, along with dys-
functions in overall nutrition-related biochemistry. Such
prominent visual findings in schizophrenia and schizoaf-
fective disorder highlight the need for more detailed visual
assessment and correction of visual deficits for first
episode psychosis patients, particularly since visual im-
pairments have already been reported in psychosis [35], in
both medicated and medication-free schizophrenic sub-
jects [36,37]. With respect to the deficit findings related to
the right distance vision in schizophrenia, it is known
that right parietal cortex and right frontal cortex exert a
stronger driving influence on visual areas of the left
hemisphere [38].
The role of vitamin D in visual deficit is understandable
in terms of its role in promoting glutamate decarboxylase
(GAD 67) expression and therefore GABA production
[39]. It also has a role in Glutathione production, with low
levels of glutathione found in vitamin D deficient animals
[40]. A reciprocal mechanism also exists between elevated
catecholamines and low vitamin D levels, with catechol-
amines priming parathyroid hormone, to release calcium
(Ca ++) ions from neuronal cells - an effect that is directly
opposed by the action of vitamin D, theoretically leading
to increased vitamin D utilization and chronically low re-
serves of this vitamin [41,42]. Taken together, these effects
of vitamin D over-utilisation by combating glutaminergic
and Ca++ excitotoxic damage and oxidative stress in
retinal and visual pathways [43] very-likely set in motion a
cycle of elevated arousal via the hypothalamic pituitary ad-
renal (HPA) pathway, resulting in still more noradrenalinerelease (with excessive noradrenaline release known to
also disrupt sensory processing pathways [44]).
Thus in a chronic state, continued draw-down on the
adrenal to produce even more catecholamines, may re-
sult in further overutilization of vitamins and eventually
adrenal fatigue, with reduced neural transmission that
further hinders visual and auditory sensory processing
performance [45]. To summarise: primary nutritional-
biochemical-oxidative stress imposes sensory processing
strain, resulting in secondary HPA activation, resulting
in mandated dopamine and catecholamine synthesis
that then remotely draws down on vitamin D reserves.
This demonstrates the potential for a vicious cycle of
poor nutrition→ low Vitamin D→ low glutathione→
increased oxidative stress and reduced GAD 67 expres-
sion, with low GABA and neuronal calcium neuro-
excitotoxicity, followed by visual pathway damage→
sensory strain→HPA axis activation→ elevated cate-
cholamines→ further increased vitamin D utilisation→
back to decreased vitamin D availability with low gluta-
thione and high calcium excitotoxic neuronal damage
explaining the underlying pathology of the hidden visual
deficits in schizophrenia. Further research in this area is
required [46].Rank II: Auditory domain
The auditory domain demonstrated the second strongest
results on ROC analysis.
This domain contained biomarkers of reverse digit span
(auditory (verbal) working memory), competing words
(intra-cerebral dichotic listening), and delayed speed of
auditory processing. This domain was also significantly
correlated with the elevated catecholamine domain, im-
plying that deficits in this domain also cause increased
activation of the HPA, resulting in further elevated cat-
echolamine release. This domain was the most strongly
related to nutritional-biochemical abnormalities such as
low folate, low vitamin D and high vitamin B12, with
low vitamin B6 demonstrating a strong specific transla-
tional relationship.
The finding of low reverse digit span (impaired auditory
working memory) has been previously documented for
schizophrenia [47]. This project also utilised the (SCAN-3)
test [48] as a measure of auditory processing disorder and
an unsuspected finding was the prevalence of impaired
competing word deficit (representing dichotic listening
disorder) in the participants with schizophrenia and schi-
zoaffective disorder. Subsequently, we found that dichotic
listening deficits have also been previously reported in
schizophrenia [49] and that reduced auditory speed of
processing has been reported in chronic, non-paranoid
schizophrenics [50]. Other literature indicates that re-
duced auditory processing speed is implicit to these
Fryar-Williams and Strobel Biomarker Research  (2015) 3:3 Page 9 of 21disorders themselves and not attributable to anti-psychotic
medication [51,52].
Low folate has been associated with sudden sensori-
neural hearing loss and folate supplementation assists
hearing in older adults [53,54]. The damaging effects of
Vitamin D lack on neural circuitry and sensory end
organ function has already been described in the visual
domain section above and this damage may well apply
to auditory sense organs and neural circuitry as well.
Low vitamin B6 was specifically related to dysfunction in
the auditory domain, which is understandable, since this
vitamin is a rate-limiting cofactor for tyrosine hydrolase
and for the dopa-decarboxylase enzyme (aromatic L-
amino acid decarboxylase) which converts L-DOPA into
dopamine [55,56]. In a setting of delayed auditory function
and HPA activation we theorise that there is an excessive
need for the brain cells and adrenal gland to synthesise
dopamine. Draw-down on vitamin B6 reserves for dopa-
mine synthesis could be predicted to be high and since
dopamine is a key activating neurotransmitter for the ear
and auditory pathway neurotransmission, it is understand-
able that deficiency due to over-utilisation of this vitamin
disturbs auditory activation and neural transmission [57].
Rank III: Catecholamine domain
This domain demonstrated a strong correlate with the
Symptom Intensity Rating (SIR) index and also produced
a strong result on ROC analysis - findings consistent
catecholamine elevation being integral to symptom-
formation and with the monoamine hypothesis of
schizophrenia [58]. However, in contrast to the dopa-
minergic hypothesis of schizophrenia [59], within the
catecholamine domain, elevated noradrenaline levels
predominated over elevated adrenaline levels and
levels of both generally predominated over dopamine
levels. Both dopamine and noradrenaline have been
found to be raised in the blood of medicated and non-
medicated patients with schizophrenia [60] and elevated
noradrenaline levels have been reported in cerebral
spinal fluid of both drug-free and neuroleptic-medicated
schizophrenic patients [61]. Sustained, elevated levels of
noradrenaline and adrenaline have also been reported in
post-traumatic stress disorder [62], which is thought to be
a traumatic response to inner confusion and anxiety
caused by thought disorganisation and hallucinatory
experiences [63]. We therefore theorise that this finding of
peripherally elevated urinary catecholamines may not only
cause sensory processing strain, but may also be reflective
of dual visual and auditory sensory strain becoming a sub-
liminal dynamic that is also an important component of
secondary HPA activation, leading to further sensory sig-
nal disruption and psychosis-formation in schizophrenia
and schizoaffective disorder. This interpretation partly fits
with the 1990 findings of Adler LE, et al. [64] and alsowith the finding of stress-related pituitary enlargement in
treated and untreated patients with schizophrenia [65-67].
It raises further important issues in the relationship to
evolutionary and developmental origins of schizophrenia
[68]. Raised catecholamines are also reported to suppress
immune system responses [69,70], a finding that fits with
reported reduced microglial activation in schizophrenia
[71]. Noradrenalin and adrenaline elevation appear
associated with mixed behavioural symptoms of anxiety
and vigilant aggression that co-occur together with
negative symptoms [72] and it is understandable that
draw-down on both vitamin D and B6 (and even on
folate reserves), may occur under the HPA axis mandate
to synthesise more catecholamines as a secondary re-
sponse to primary auditory or visual sensory strain. Evi-
dence also exists that whilst low levels of Noradrenaline
positively modulate cortical neurotransmission, at
greatly increased levels, Noradrenaline neurotransmis-
sion is disrupted [72-74] which can be considered as a
basis for fronto-temporal dysconnectivity, attentional
disorganisation with impaired frontal cognitive function
[75,76], temporal isolation and psychosis.
High Cu/Zn ratio and low vitamin D levels within the
overall nutritional-biochemical domain exert strong
translational effects upon the elevated catecholamine do-
main. This is to be expected, since copper is a cofactor
for noradrenaline synthesis from dopamine and reports
exist of high copper and low zinc associated with nor-
adrenaline excess in schizophrenia [77,78]. Animal models
also demonstrate vitamin D deficiency in relationship to
elevated brain dopamine and noradrenaline levels [42].
The means by which vitamin D reserves may be over-
utilised through combating the effects of catecholamine-
inducted parathyroid hormone activation, has already
been described [40,41].
In this study low vitamin B6 was specifically related to
high dopamine levels, which is understandable since B6
is required as a cofactor at two enzyme levels as a cofac-
tor for dopamine synthesis by tyrosine hydroxylase and
for conversion of L DOPA into dopamine by the enzyme
DOPA decarboxylase. The latter reaction is extremely
important since L-DOPA is the only peripherally synthe-
sized catecholamine capable of entering the blood brain
barrier so its synthesis is the rate-limiting step for nor-
adrenalin synthesis within the brain [55,56]. Apart from
low vitamin B6 from poor nutritional intake in poorly
functioning schizophrenic states [79], low vitamin B6
findings may be due to increased utilization of B6 under
HPA imperative to increase L-Dopa and dopamine syn-
thesis, triggered by sensory-strain-HPA-system-activation
in order to manufacture more noradrenaline [80]. Given
such an HPA imperative to synthesise more noradrenaline,
the numerous research findings of elevated dopamine in
schizophrenia, leading to the dopamine hypothesis of this
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a necessary precursor of noradrenaline.
Rank IV: HPL/creatinine domain
Hydroxyhemopyrroline-2-one (HPL) emerged as a legit-
imate biomarker on ROC analysis. In a similar manner
to translational relationships for catecholamines, HPL
received strong translational influence from high Cu/Zn
ratio and low vitamin D levels. Pyrrole products are
ubiquitous in tissue biochemistry and HPL’s presence in
urine is linked to oxidative stress and to low levels of
vitamin B6 and zinc [81], which can further deplete B6
reserves and elevate free copper levels, respectively. Urin-
ary HPL is thought to arise as an abnormal product of
haeme metabolism induced by haemeoxidase under con-
ditions of extreme oxidative stress where the porphyrin
moiety of haemoglobin becomes degraded or where there
is abnormal porphyrin synthesis [82-85]. When injected
into rats and mice, HPL causes reduced activity, head
twitching and backward locomotion (retreat) behaviour
[86] and patients with elevated HPL levels report symp-
toms of anxiety, depression, low stress-tolerance and
mood swings. HPL may also be stress and catecholamine-
related and as such, elevated levels may be disorder-non-
specific [87]. The structure of the HPL molecule has
belatedly been discovered [88] and these findings invite
further investigation of this oxidative, haeme-related mol-
ecule and its reported psychiatric effects.
Rank V: Nutritional-biochemical domain
biochemical/biochemical biomarkers such as elevated free
copper: zinc ratio, low vitamin B6 activation, low vitamin
D and low folate levels, which on the “divide by three” test
failed to exert sufficient individual strength to gain firm
diagnostic association, were still able to demonstrate
sufficient cumulative strength in terms of odds ratio of
diagnostic association to have significant correlation with
symptom severity.
While red cell zinc failed to produce an independent
finding on ROC analysis, elevated serum free copper, in
ratio with red cell zinc, was a biomarker of schizophrenia
or schizo-affective disorder, confirming the hair-analysis
findings of Ghanem et al. in 2009 [77]. Elevated free cop-
per contributes to neuronal damage in circuits responsible
for sensory-processing [89] and copper levels may also be
influenced by reduced ceruloplasmin (copper binding pro-
tein) levels which has been linked to psychosis [90]. Free
copper is redox active in the body and also contributes to
reactive oxygen species and oxidative stress [91]. It also
blocks the action of cystathione beta synthase (CBS)
(Figure 1), an enzyme located upstream of glutathione
production, preventing the formation of this major anti-
oxidant for the brain [92]. Copper also binds to cholesterol
producing an oxidative product 17-hydroxy cholesterolthat is toxic to neurons [93]. Given these multiple neuro-
toxic and oxidative stress-related effects of elevated free
copper, it is understandable that it can play a strong role in
degradation of neurones in sensory-processing circuitry.
Zinc plays a reciprocal role to copper since it com-
petes for metallothionein binding protein and acts as a
defence against copper by inhibiting its absorption from
the gastrointestinal tract [94]. Copper is a cofactor for
the enzyme which synthesises noradrenaline from dopa-
mine (Figure 1), which explains why low zinc facilitates
high free copper which is then associated with elevated
norepinephrine [78]. Animal models also suggest that zinc
facilitates copper/zinc superoxide dismutase in blocking
cell apoptosis signalling [95] and that zinc deficiency
impairs fatty acid and myelin composition [96,97].
This research found that schizophrenic and schizo-
affective patients may be extremely sensitive to inadequate
levels of activated B6, since its ROC determined cut-off
value occurred within the normal laboratory reference
range. This is theoretically due to the many co-factor roles
of B6 across biochemical pathways related to monoamine
synthesis and prevention of oxidative stress. Indeed, in-
adequate levels of activated B6 may be reflective of its
increased utilisation in these multiple biochemistry
pathways. For instance, in the initial stages of dopamine
synthesis, the enzyme tyrosine hydroxylase requires B6
as a cofactor [98] and downstream to this, L-Dopa is the
only catecholamine precursor to enter the central nervous
system being converted into dopamine by the enzyme
DOPA decarboxylase, with vitamin B6 as a required cofac-
tor for this reaction (Figure 1), [55,56]. In the transulfu-
ration pathway (Figure 1) the enzymes cystathione beta
synthase (CBS) and cystathionase also require vitamin B6
for the synthesis of the brain antioxidant glutathione via
[99]. Such B6 over-utilization with relative deficiency
may then inhibit the action of the enzymes CBS and S-
adenosylhomocysteine hydrolase (SAHH) [100], leading
to back-ups in the transmethylation cycle and methy-
lation cycle with elevation of homocysteine and S-adenosyl
homocysteine (SAH) [101], respectively. Indeed, when such
effects coincide with free copper toxicity and further CBS
inhibition [89,91], glutathione synthesis may then be dras-
tically reduced and free radicals damage neuronal circuitry
made vulnerable in this setting of oxidative stress. In such a
setting, high copper also promotes further noradrenaline
synthesis from dopamine [78] whilst elevated SAH con-
tributes to raised catecholamine levels by directly inhibit-
ing cathechol-o-methyl-transferase (COMT), [102-104].
With inhibition of this COMT enzyme that is responsible
for the final step of catecholamine metabolism (Figure 1),
catecholamine intermediate metabolic products accumulate
and break-away metabolism of backed-up intermediate-
metabolites result in abnormal neurotoxic products and
further cytotoxic neuronal consequences [105].
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677 T) polymorphism demonstrated a positive significant
correlate for high homocysteine levels, however MTHFR
polymorphism, along with plasma homocysteine, urine
HVA and MHMA were not successful as biomarkers on
ROC analysis. Though weak enzyme dynamics due to
thermo-lability of the MTHFR 677 T polymorphism has
received much research attention with regard to schizo-
phrenia and homocysteine elevation [106], there is evi-
dence that contradicts this finding [107]. The MTHFR
polymorphism is linked to deficiency of its product 5-
methyltetrahydrofolate (5-MTHF) and in settings where
enzymes in other homocysteine metabolism pathways
are also inhibited, backed-up, elevated homocysteine
may occur (Figure 1). Such findings have been reported
in schizophrenia [106] and it may be that our ROC find-
ing of elevated vitamin B12 represents a compensatory
reaction of unknown mechanism designed to assist me-
thionine reconstitution from homocysteine. In a setting
of MTHFR polymorphism homozygosity with lack of
5-MTHF product, elevated vitamin B12 may be a ne-
cessary compensation in order to sustain methylation
cycle precursors for maintenance of S–adenosyl methio-
nine (SAMe) levels (Figure 1).
Low red cell folate was also a biomarker in this study
and this finding has been previously reported in schizo-
phrenia [108] where poor diet may convey vulnerability
for low methylation and low SAMe (Figure 1), [109]. SAMe
also stabilises CBS in the transulfuration pathway, protect-
ing this pathway against glutathione depletion and therefore
against oxidative stress [110].
Folate and vitamin B12 (cobalamin and methylcoba-
lamin) have important roles in sustaining production of
SAMe, which in turn serves to prevent oxidative stress
and catecholamine elevation by serving to stabilise CBS
and also as a cofactor for catechol-o-methyltransferase’s
(COMT) metabolism of catecholamines [111]. Therefore
relative unavailability of SAMe due to colluding influ-
ences of homozygous MTHFR polymorphism, low folate
or low B12 levels may allow oxidative stress and impair
COMT activity, explaining our correlate and ROC find-
ings of elevated HPL and elevated catecholamine levels.
The effects of oxidative stress and elevated catechol-
amine levels have been well documented in literature
and are also noted in psychotic children [112-114].
In contrast to the above findings and their biochemical
interpretations, other research findings have not found
notably elevated homocysteine levels in schizophrenia
[115]. Indeed in this research project, homocysteine failed
to reach ROC biomarker status and this may be note-
worthy in the collateral setting of positive ROC’s findings
for elevated free copper to zinc ratio. This is because
elevated free copper inhibits the homocysteine metabolis-
ing enzyme (cystathione-beta-synthetase (CBS) in thetransulfuration pathway leading to glutathione synthesis
[91]. A further plausible explanation is that since vitamin
B6 is required for homocysteine synthesis, low vitamin B6
may accompany low homocysteine. If this is so, then the
causal explanation that COMT inhibition in schizophrenia
may occur via SAMe unavailability for COMT facilitation
[111] is less likely and an alternative explanation is re-
quired. Since SAH-hydrolase (SAHH) requires vitamin B6
for S adenosyl homocysteine (SAH) conversion to homo-
cysteine (Figure 1), SAH is more likely to accumulate in a
setting of low vitamin B6 [101]. Then in a setting of
retrograde, elevated SAH, the remotely situated COMT
enzyme which metabolises catecholamines is directly
inhibited [103,104]. Taken together, these explanations
bring together our ROC biomarker findings of elevated
catecholamines, low vitamin B6, high free copper and
high vitamin B12, providing a more cohesive dynamic
understanding of potential interactions and causes. Finally,
the accompanying finding of failed biomarkers for urine
HVA and MHMA reflects the tendency for elevated
catecholamine intermediate metabolic products to find
break-away metabolic pathways in a setting of their
inhibited end-stage COMT metabolism. These abnormal
metabolic pathways unhappily resulting in neurotoxic
intermediate metabolites which can contribute to loss of
neuronal density in schizophrenia [105,116].
In summary, visual and auditory sensory processing
systems in this study demonstrate peripheral deficits and
prematurely aged, delayed processing that appears trans-
lationally related to folate, B6 and D vitamin-deficiency,
copper-related neural excitotoxicity and oxidative stress.
These abnormalities then accumulate to contribute to
the fundamental architecture of schizophrenia and schi-
zoaffective disorder. Sensory processing strain may then
initiate HPA axis activation, leading to a cycle of ele-
vated catecholamine synthesis with inherent overutiliza-
tion of vitamin cofactors and further depletion of their
body reserves. This then initates a runaway process of cat-
echolamine elevation, which may occur in a setting of S
adenosyl homocysteine (SAH) inhibition of the catechol-o-
methlyltransferase (COMT) enzyme. Inhibition of this
catecholamine-metabolising enzyme then allows to
build-up of elevated catecholamines and break-away
neurotoxic catecholamine metabolites that inflict further
damage on sensory neurones (Figure 3).
Limitations
One focus of this research was to use biomarker discovery
to characterise schizophrenia and schizoaffective disorder.
To avoid confounding variables many exclusion criteria
were imposed which slowed recruitment and resulted in
a small discovery data-set. Small sample size, together
with non-normal data distribution for many variables,
precluded use of principal component analysis, latent
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and Spearman’s analysis were used instead to identify
promising biomarkers and their relationships. Sequen-
tially collapsing the data through ROC analysis and then
regression analysis, has potential for loss of some data
strength. Though case–control study designs have
inherent susceptibility to prevalence and selection bias
[117,118], they are allowable for a discovery data-set
[119] and have a respectable record in discovery re-
search [120] for low period prevalence disorders, such
as schizophrenia (0.35 per 1000) [121].
Difference in selection processes may well have
been offset by the random nature of success in the
recruitment process itself, incurred by participant fail-
ure to meet the multiple exclusion criteria combined
with a refusal-to-consent ratio of 4 to1, for approached
patients and controls alike. Also, the application of
this design to only one bracket of psychotic disorders
(schizophrenia and schizoaffective disorder) in this
project is limiting, since it is not known whether the
ROC variables discovered for these conditions are
disease specific or also occur in other mental illness
states.
The use of the DSM IV as a diagnostic tool for case
selection may also be a confounding variable, since
diagnoses may range across spectrum and boundaries
and thresholds for diagnosis are yet to reach optimal
standards for categorisation [122].
A further limitation of this project was that assessors
undertaking rating scales and neurophysiological mea-
sures, were functioning in a real-world clinic-setting, so
were not blind to participants’ patient or control status.
The full effect of confounding variables upon results
of this research was also not fully assessed. For instance,
although rigorous efforts were made to exclude substance-
related diagnoses, it is known that alcohol misuse is often
under-reported by patients [123], and has a known associ-
ation with low folate, high B12 and elevated catecholamine
levels [124,125]. It was not possible to control for partici-
pant smoking in this project and smoking also has been
variably reported to effect monoamine oxidase levels
[126], which can theoretically influence monoamine levels.
Though fasting biological samples were collected for this
study, there was no longer-term control or assessment of
dietary intake, which, in principle, could affect reserves of
vitamins, minerals and monoamines [127]. Though par-
ticipant assessments took place within a 4 day window,
it is possible that variance in relationship to a patient’s
stress or activity state, may have effected monoamine
levels and other related-variables, over the period of
assessment [128].
Despite biochemical pathway linkages and the strong
correlation of elevated catecholamine biomarkers with
Symptom Intensity Rating (SIR) as an indicator ofclinical severity, the role of medication as a confounding
variable in this project cannot be fully excluded. Although
there is widespread research evidence that antipsychotic
medications increase catecholamine metabolic turnover
and reduce dopamine and noradrenaline levels [129], evi-
dence regarding antipsychotics such as Quetiapine is less
certain [130]. By blockage of the dopamine-2 receptors
and antagonism of alpha 1 adrenergic receptors Quetiapine
contributes to suppression of hyperdopaminergic-related
positive symptoms in acute schizophrenia [131], 132
and brings about profound hypotension in overdose,
from which reversal and rescue can only be achieved by
noradrenaline [132]. However this antipsychotic has been
contrastingly reported to increase dopamine and nor-
adrenaline levels in the rat cortex [133]. The exact extent
of pharmacological action of sodium valproate is also
inconclusive. From its action on GABA, and its efficacy in
mania treatment, the mechanism of sodium valproate
action is presumed to involve reduction of catecholamine
levels. Also, since catecholamines normally promote beta
oxidation of fatty acids, reduction of catecholamine levels
by valproate is proposed as the mechanism for valproate-
associated weight gain [134]. However, evidence from rat
and ox brain experiments suggests that sodium valproate
may increase monoamine levels [135,136] whilst a con-
trasting trend is reported from mice experiments [133]
and a human CSF study indicates that sodium valproate
may increase dopamine metabolism [137], theoretically
decreasing dopamine levels.
Although the ubiquitous, oxidative-stress related mol-
ecule HPL earned its place as a discovery biomarker
additional biomarkers for oxidative stress, future candi-
date markers could be widened to include other markers
of oxidative stress. Similarly, other neurotransmitters
and measurement of SAMe:SAH levels and COMT
activity levels that would further validate putative bio-
chemical linkages.
Elevated urinary catecholamine biomarkers identified
in this study cannot be directly related to brain neuro-
transmitter changes, since fully-synthesized monoamines
do not cross the blood–brain barrier even though their
precursor substance, L-Dopa is capable of this transition
[80]. Spot-urine collection, as a method for peripheral
monoamine analysis, has also attracted criticism [138]
though it is practical in a psychiatric setting, is success-
ful in paediatric settings [139,140] and is gaining ground
as a useful analytic method relating to body biochemis-
try [141].
Due to all these considerations, the optimal means for
replicating and validating this project’s discovery bio-
markers is via a large, well-characterized, prospective,
multi-site-clinic trial on a single series of consecutive pa-
tients, with blinded assessors and an emphasis on collect-
ing data from ultra-high risk medication naïve subjects.
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This research is a pioneering effort to quantify bio-
markers for schizophrenia and schizoaffective disorder
across several domains of function. It introduces an
objective, quick, simple-to-apply clinical assessment tool
for understanding a patients underlying pathology. Bio-
markers were discovered for some variables such as di-
chotic listening disorder and asymmetric distance vision
that are not easily clinically recognised and therefore
represent largely unmet needs within current clinical
assessment and practice for psychosis. Since remediation
techniques are already in existence for these disorders,
such findings hold potential for reduced treatment-
resistance, cost-burden, social stigma and improved
relapse-prevention.
Correlative findings demonstrate that schizophrenia
and schizoaffective disorders relate to a matrix of subtle,
sub-clinical disorders ranging from the intra-cellular
nutritional biochemistry dysfunction to oxidative stress
and elevated catecholamine neurotransmitter levels.
These then link up translationally with dysfunction in
both peripheral and central domains of neuro-sensory
processing.
Visual processing tracts are damaged and their pro-
cessing is delayed in schizophrenia and schizoaffective
disorder. This has a strong bidirectional relationship to
catecholamine excess, particularly of noradrenaline and
a moderate relationship to pathology in cellular nutritional
biochemistry and oxidative stress domains.
Auditory processing tracts are also substantially de-
layed and dichotic hearing is adversely affected. More-
over, this damage is most strongly related to pathology
in the nutritional domain of biochemistry.
The implications from this research is that visual and
auditory sensory processing systems are prematurely
damaged and aged by vitamin-deficiency, copper-related
neural excitotoxicity and oxidative stress and that defi-
cits in these abnormalities fundamentally contribute to
the biochemical architecture of schizophrenia and schi-
zoaffective disorder. Sensory neuronal damage and strain
may then have secondary potential to initiate HPA axis
activation, followed by a cycle of elevated catecholamine
synthesis with inherent overutilization of vitamin cofac-
tors and depletion of their body reserves. This initates a
runaway process of catecholamine elevation where
break-away neurotoxic metabolites, high free copper and
oxidative stress combine to further ramp up dysfunction
of neurosensory pathways. Subliminal recognition of
processing strain within these pathways then activates
the hypothalamic pituitary adrenal axis, which together
with high free copper levels, pushes catecholamine syn-
thesis towards higher and higher noradrenaline levels.
Eventually ramped-up levels of a noradrenaline induce
disconnection in visual and auditory sensory pathwaysculminating in sensory attentional disorganisation, low
visual span and frontal and temporal isolation with
psychosis.
Although current research indicates that many of these
findings occur irrespective of medication, validation of
these biomarkers is warranted in ultra-high risk medica-
tion naïve subjects in a larger, well-characterized, cohort
with blinded investigation. Deeper understanding of bio-
markers will widen and objectify our understanding of
psychosis and improve targeted remediation of the sub-
structure of schizophrenia and schizoaffective disorders.
Methods
Study design
A case–control study design and multiple exclusion
criteria, were used to select cases and exclude organic
causes and variables which could influence outcome
measures for selected markers. In this manner, we reduced
possible aetiologies of schizophrenia and schizo-affective
disorder to their core functional conditions. Using such
highly characterised cases, we hoped to unmask some of
the multiple, subtle, cumulative variables that could con-
tribute to these disorders.
Participants
All participants were informed of the goals, assessment
procedures and funding of this study and provided written
consent. Ethics permission for the study was obtained
from the hospital ethics committee. Participants were re-
cruited between 2010 and 2014 from The Queen Elizabeth
Hospital, Woodville, South Australia and from satellite
mental health clinics in the western catchment area of
Adelaide, South Australia. They were from multi-ethnic
backgrounds with an age-range between 18 and 60 years
of age. Similarity of psychotic symptoms occurs in both
schizophrenia and schizo-affective conditions and their
diagnoses were made with roughly equal incidence in the
project setting at a 1.2 to1 ratio, respectively. Recruitment
of both psychotic conditions allowed for sufficient recruit-
ment numbers to occur under the strict exclusion criteria
imposed, whilst also allowing scope for later analysis of
depressed or manic affective symptoms in relationship to
biomarkers discovered. Recruitment and assessments were
conducted directly and by phone across hospital, research
institute and community clinic settings. Control parti-
cipants were recruited by phone from a volunteer popu-
lation associated with the hospital and drawn from the
same catchment area as patients.
Patient recruitment and sample selection
Non-detained ward patients in partial remission but with
residual symptoms of psychosis, were recruited and
assessed in the expected last week of their admission, by
which time they were in a less severe state of psychosis
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After 7 early dropouts due to declining mental state, a
total of 82 symptomatic participants (cases) were re-
cruited and completed assessment. Early statistical ana-
lysis of confounders required that 15 participants on
SSRI or SNRI antidepressant medication were excluded
from further analysis, due to their suppressive effect on
catecholamine levels, therefore the number of partici-
pants used in the final statistical analysis was 67.
Patients were included in the study if they received a
diagnosis of schizophrenia or schizoaffective disorder,
made by a consultant psychiatrist in the ward or commu-
nity satellite clinic setting, DSM IV-R diagnoses were
checked against a DSM-IV-R symptom checklist at the
recruitment stage, in order to confirm that a correct diag-
nosis had been made. Clinical appraisal of a patient’s judg-
ment capacity and orientation in time, place and person
was undertaken during recruitment, in order to confirm
capacity to consent and exclude delirium. Informal exam-
ination to exclude ocular-muscle dysfunction, hand, fore-
arm and shoulder dysfunction was also conducted at this
stage, in order to ensure that a patient was free to proceed
to neuro-physiological tests in the absence of rigidity,
dyskinesia, tremor or postural instability as a result of
extra-pyramidal side-effects from antipsychotic medica-
tion [142]. Persons medicated with Clozapine, Olanzapine,
anti-histamines or vitamin therapy were excluded, since
these variables had potential to confound biochemical re-
sults for one of the candidate markers. Participants taking
antipsychotic-agents with lesser-effect on histamine recep-
tors (Zuclopenthixol, Modecate, Amisulpride (Solian) and
Risperidone) were however included. The only exception
to this was the inclusion of seven patients on Quetiapine.
Mood stabilisers were allowed and four patients received
sodium valproate. Pharmacotherapy of patients remained
stable during the assessment period which was usually
completed on the same day as recruitment and in a few
cases, within four days of recruitment. Patients were also
excluded from the study if they had a recent or unresolved
history of alcohol or other substance abuse, since this can
confound biochemical and particularly neurotransmitter
results. Persons with upper respiratory tract infections,
visual or auditory disability were excluded since these con-
ditions could effect auditory or visual sensory processing
tests. Persons with intellectual, clinically-documented or
descriptive-history of head injury with unconsciousness or
hospitalisation, were also excluded, since these conditions
may effect ability to comply with tests or be complicated
by psychosis. It was considered impossible to control for
smoking as a variable and have any chance of sufficient
patient recruitment.
In order to minimise severity bias by comparison of
very-sick with well controls in this case–control study,
ward patients were recruited within a week of theirexpected discharge back into the community from which
controls were drawn and selection bias was minimised
by recruiting some clinic patients by phone and assessing
them in the same community setting as the recruited
controls.
Control recruitment and sample selection
A total of 72 control participants, were recruited with the
assistance of the Population Research and Outcomes Stud-
ies (PROS) Unit of the University of Adelaide. These par-
ticipants were volunteers, from the same catchment area
as patients, affiliated with the Department of Medicine and
the North West Adelaide Health Study (NWAHS), for
research purposes. Using the same exclusion protocol as
for patients, these participants were age-stratified and
randomly recruited by phone contact, over the same as-
sessment period as patients. In a low prevalence condi-
tion such as schizophrenia with a period prevalence
0.35 per 1000,none of the controls reached threshold
for schizophrenia or any DSM diagnosable mental ill-
ness, but they were rated for any subclinical symptoms
by a psychiatrically-trained assessor who was not blind
to their asymptomatic status, but was blind to all bio-
logical test results at the time of rating. Five presenting
control participants were assessed, but had their data
excluded due to their not meeting basic vision or hearing
criteria for participation in the study. In order to obtain
younger controls for age and sex matching, two asymp-
tomatic volunteers who resided within the same NWAHS
catchment area, were recruited from a local surf life-
saving club. Although recruitment methods differed be-
tween cases and controls, the control sample used for the
final analysis was drawn from the same catchment area
and outpatient environment as the patients and the sam-
ple for final analysis consisted of 67 cases and 67 (72–5)
controls for which baseline sample characteristics are
provided in Table 1.
Other participant assessment procedures
Together with a review of the participant’s case notes, a
standard interview protocol collected demographic infor-
mation and information related to development, organic,
biochemistry and sensory-processing disorder. Also recor-
ded was absence or presence of developmental difficulty
or learning delay, medical co-morbidity, and head injury,
family history of mental illness, glasses or hearing aids.
Symptoms in the Brief Psychiatric Rating Scale (BPRS)
and the Positive and Negative Syndrome Scale for Schizo-
phrenia (PANSS) - were amalgamated in the interest of
reducing assessment time. Using this rating tool, each
symptom was rated from 1 to 7 for intensity. These
ratings were then summated to give an overall symptom-
intensity-rating (SIR) index, which was taken as a measure
of clinical severity. Hospital and clinic ratings were made
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index laboratory and sensory-processing test results, but
not to patient status, at the time of rating. Ratings were
checked by DSM diagnostic checklist. Rating for control
participants were made by one psychiatrically-trained
assessor. It was not considered practical in the real world,
for raters to be blinded to the diagnostic status of the
participant, since many patients were unable to mask their
condition, due to residual psychotic symptoms.
Sensory processing assessment
Reverse digit span working memory and spatial working
memory were selected because of their known association
with schizophrenia [143,144]. Other sensory processing
tests were selected based upon clinical experience with
patients with schizophrenia, where visual and auditory
processing speed deficits had been observed in many cases
and suggested that cross-talk between auditory processing
disorder and schizophrenia might occur.
After determining visual and hearing acuity, all parti-
cipants were assessed for selected sensory and cognitive
variables related to auditory and visual processing.
Assessments were conducted in auditory and visual
domains, at a time separated from both blood and
urine collection and within two hours of such biological
sample-collection. The methods of sensory processing
assessments for this project are outlined in Tables 5 and 6
and shown in Figures 4 and 5.
Where applicable, visual assessment was conducted
using the participant’s usual glasses and alternate-Table 5 Summary of visual assessment methods
Assay/Assessment Method
Visual
Near vision acuity test Sussex Vision test of ne
card SNT-3000-L, 2009–
Visual (symbol) span Increasing number of s
in a standardised order
score reported as the a
symbols recalled in the
Distance vision (Binocular distance vision acuity) Right distance vision, th
with 20 seconds inter-t
Threshold visual speed of processing
performance as a percentage of age
Person tested sees two
presented from left-to-r
occasions, and must de
first. The inter-stimulus
flashes is shortened by
is correct, otherwise it i
rating, is provided, con
Performance-age is sub
actual age and the resu
test subject is multiplie
(Expresses visual processing speed in terms
of the visual processing system’s relative age)
Shortest interval of time a person can notice
between the order of presentation of two optical
stimuli. Speed of visual order processing increases
with age. For adults between the range of 18 and
60 years, the normal range for visual speed of
processing is 24 to 72 milliseconds). For adults
between the range of 18 and 60 years, the
normal range for visual speed of processing
is 24 to 72 milliseconds.cover-test was conducted prior to visual testing, to
exclude visual fixation disparity (phoria or tropia) as
a potentially confounding variable [145]. Visual as-
sessments included near and distance visual acuity,
visual attention span, speed and accuracy of visual
processing.
Auditory assessments (Table 6) were conducted in a
quiet room (ambient noise level 20 dB) and preceded by
examination of the external auditory meatus to exclude
obvious pathology or sebum obstruction. Audiometry
examination was conducted using the MAICO Audio-
gram MA 40 [146], at 250 Hz to 4000 Hz to determine
hearing deficits (defined as air-bone conduction gaps >
10 Hz and/or threshold abnormalities > 500 - 1000 Hz)
and laterality differences. Auditory processing assessment
outcome measures were of acuity, attention, and threshold
speed and accuracy of auditory processing. All assess-
ments were performed by a neuro-psychiatrically trained
assessor who was blind to laboratory results. It was
considered impractical to blind the assessor to participant
status, as residual symptoms of psychosis were obvious
to the trained observer. Apart from the prerequisite
audiogram assessment, equipment is compact and carried
in a suitcase (Figures 4 and 5).
Biochemical assays and specimen collection
It was considered important to use clinically-accessible,
commercially-available tests to assay biochemical markers
in this study. Investigation involved blood and urine sam-
ples collected from all participants. Biochemical collectionLaboratory/Reference
ar vision. Near vision test
2011.




from left to right. Test
bsolute number of visual
correct order.
Based on Visual Symbol subset test
of WMS-IV (Weschler 2009)
en left distance vision,
est interval.
The Snellen-Chart (Snellen 1860)
brief flashes of light randomly
ight or right-to-left on multiple
cide which light flash appeared
time interval (ISI) between the
computer algorithm, if the answer
s lengthened. A performance-age
figured against norms-for-age.
tracted from the individual’s
lt divided by the age of the
d by 100.
Brain Boy Universal Professional
instrument (MediTECH 2010)
Table 6 Summary of auditory assessment methods
Assay/Assessment Method Laboratory/Reference
Auditory
Reverse digit span With gaze aversion by listening participant and tester,
digits are read in set sequence. The tested participant
is asked to repeat them in reverse order. Reported as
the absolute number of digits correctly recalled in
reverse order.
Subset of Wechsler Adult
Intelligence Scale III
(Wechsler 1997)(Measures auditory (verbal) working memory)
Normal range is 6 to 7
Competing words performance for age as a
percentage of age
A voice-over CD and earphones test ability to correctly
identify both of two competing-words (CW), delivered
separately to the right and left ears. Using this test’s
normative-for-age database, the difference between each
test subject’s expected and actual performance-for-age
was calculated, and this was then divided by the actual
age of the test subject, and multiplied by 100.
SCAN-3 (Keith 2009)
(Intra-cerebral dichotic listening performance
for processing of auditory information)
Normal ranges vary with age
Threshold speed of Auditory processing as
a percentage of age
Person tested hears two clicks, randomly presented from
right to left and left to right side, presented through
headphones. By pressing a right or left button, a decision
must be made from which side the dual-stimulus originates.
If the answer is correct, the inter-stimulus interval between
flashes (ISI) is shortened, otherwise it is lengthened. The
auditory order threshold is the shortest ISI a person can correctly
differentiate between two auditory impressions. A read-out of
the threshold speed of auditory (order) processing is provided,
along with a norm performance-age rating. Auditory speed of
(order) processing performance as a percentage of age is calculated by
subtracting the norm-for-age from the performance-age, divided




(Speed of auditory processing systems
relative to age)
Speed of auditory processing reduces with
age. For adults in the age range of 18 and
60 years, the normal range for auditory
speed of processing is 46 to 72 milliseconds.
Fryar-Williams and Strobel Biomarker Research  (2015) 3:3 Page 16 of 21methods are documented in Table 7. All biochemical-
testing was conducted by independent commercial labora-
tories that were blind to participants’ case or control status
and all participant raters and assessors were blind to la-
boratory results. The theoretical background for selection
of biological markers are outlined below and elaborated in
Figure 1.
Baseline, fasting, spot-urine for biochemical assays of
dopamine, noradrenaline and adrenaline as well as theirFigure 4 Office assessment equipment.metabolites homovanillic acid (HVA) and methoxy-
hydroxymandelic acid (MHMA) and the serotonin me-
tabolite 5-hydroxyindoleacetic acid (5-HIAA), were col-
lected. As part of this analysis, urinary creatinine was
determined as a urine concentration standard and this
standard was also used for urinary hydroxyhemopyrroline-Figure 5 Sensory speed of processing equipment.
Table 7 Summary of biochemistry tests and methods with website links and literature citations




Spot-baseline (fasting) urinary neurotransmitter
testing (second void morning), snap-frozen to
minus 30 degrees and analysed by mass
spectrometry, using nanomols per millimol of
urinary creatinine as a standard.
SA Pathology, Adelaide, South Australia.
Whiting MJ. 2009. Simultaneous measurement
of urine metanephrines and catecholamines
by liquid chromatography with tandem mass
spectrometric detection. Annals of Clinical
Biochemistry, 46:129-136
Creatinine Spot urine specimen from the same void as
biogenic amines, expressed in (millimols per Litre)





Spot urine (second void morning) in ascorbic acid,
snap frozen (−30C) and light-protected. Colorimetric
method at 540 nm, following solvent extraction and
reaction with Erich’s reagent. (micrograms per decilitre).
Applied Analytical Laboratories, 8/26 Nestor
Drive, Meadowbrook, Queensland,
Australia. +61 7 3133 1615.
Nutrition-Biochemistry
Vitamin D ( 25-OH) Diasorin Liason assay kit, for use on the Liaison
platform (nmol/L).
Clinpath Laboratories, 19 Fullarton Rd,
Kent Town. South Australia
5067 +61 8 8366 2000.
Serum total Vitamin B12 Competitive Electrochemiluminescent Immunoassay.
Roche Modular E 170
Clinpath Laboratories. As above.
Automated Immunoassay Analyser, using Roche
Vitamin B12 Reagent (pmol/L).
Red Cell Folate Competitive Electrochemiluminescent Protein Binding
Assay, using Roche Modular E 170, using Roche Folate
Red Blood Cell (RBC) Reagent and Roche Folate RBC
Haemolysing Reagent. on Automated Immunoassay
Analyser (nmol/L).
Clinpath Laboratories. As above.
Vitamin B6 (Pyridoxal-5’-phosphate
coenzyme form)
Whole blood High Pressure Liquid Chromatography
with fluorescent detection. Chromsystems Vitamin B6
in Whole Blood High pressure Liqid Chromatography
Reagent Kit. Waters Alliance 2695 Separations Module.
Waters 474 Fluorescence Detector (nmol/L).
Sullivan Nicolaides Pathology
143 Whitmore St, Taringa. Queensland
4068. Australia. +61 7 337 8666
Serum Copper Flame Atomic Absorption Spectrophotometry. Douglass Hanly Moir Pathology
Varian AA-240FS (umol/L). 14 Griffnock Avenue, Macquarie Park.
New South Wales 2113. +61 2 9855 5222.
Red Cell Zinc Inductively coupled plasma mass spectroscopy (ICP-MS),




Serum Ceruloplasmin Immunoturbidimetric method, using 6 K91-30 Multignet
Caeruloplamin Kit and Abbott Architect ci16000
analyser (g/L).
Douglass Hanly Moir Pathology.
As above.
Percentage Free Copper/Red Cell
Zinc
Percentage of free copper in the serum calculated by an
equation based on the molecular and atomic weights
of ceruloplasmin and copper (one ceruloplasmin molecule
binds to six copper atoms). The ratio of the percentage
free copper to red cell zinc was calculated as “percentage




MTHFR Ala222Val (C677T) methyl
tetrahydrofolate reductase
polymorphism
Real time PCR analysis Douglass Hanly Moir Pathology.
Roche Diagnostics Light-Cycler 480 kit. Using TecnoBiol
reagents, Sigma probes and primers on Roche LC480 analyser.
As above.
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Table 7 Summary of biochemistry tests and methods with website links and literature citations (Continued)
Plasma homocysteine Ice transported EDTA sample. Competitive Chemiluminescent
Immunoassay, using Seimens Homocysteine reagent on
Seimens Advia centaur Automated Immunoassay (umol/L).
SA Pathology. +61 8 8222 3000 As above.
Serum histamine Beckman Coulter Radio Immunoassay, using Beckman Coulter




Fryar-Williams and Strobel Biomarker Research  (2015) 3:3 Page 18 of 212-one (HPL) - a metabolite reported in schizophrenia that
is considered to be indicative of oxidative stress. Fasting
blood was also collected for vitamins and mineral co-
factors and intermediate substances related to folate and
methionine (one-carbon) cycles which have theoretical
potential to exert cumulative effects on neurotransmitter
synthesis and metabolism (Figure 1). These allied pathways
are effected by enzyme cofactors vitamin B6, B12, red cell
folate], serum copper and red cell zinc], with other sub-
stances such as plasma homocysteine, serum ceruloplas-
min, serum histamine], and serum methyltetrahydrofolate
reductase (MTHFR 677 C- > T) gene polymorphism.
Assays were also performed for vitamin D, which has a
proven epidemiological link with schizophrenia In order
to ensure that urine neurotransmitter levels were not
unduly affected by hypothalamic-pituitary axis (HPA)
activation there was a minimum of two hours separation
between blood collection and urine collection.
Data analysis
Lack of normal distribution in the ROC variables neces-
sitated the use of EsyFit software [30] to determine
forms of data distribution and other characteristics such
as mean, median and mean absolute deviation. Other
statistical analysis was conducted using XLSTAT [29] for
descriptive statistics, Receiver Operating Curve (ROC)
analysis and odds ratio analysis of association of ROC
variables and domains with a diagnosis of schizophrenia
or schizoaffective disorder, at a 95 per cent level of
confidence. A ROC curve is a graphical summary of
discriminatory accuracy between a population with a
disease and a population without the disease. The ROC
curve describes the relationship between the true posi-
tive fraction (sensitivity) and the false positive fraction
(one minus specificity) for different positivity thresholds
[41,42]. Criteria for candidate markers to approach
biomarker-status are a ROC AUC lower boundary of 0.6
and an odds ratio of > 2, at 95 per cent level of confi-
dence. We also included outcomes for variables falling
slightly short of these criteria which nevertheless con-
tributed to raising the AUC within any particular do-
main. The strength, direction and covariance-potential
of key ROC-established-variables and domains, were ex-
plored in relationship to other outcome-variables, using
Spearman’s Correlation. Due to abnormal distributions
and low sample size, principal component analysis andlatent variable analysis were not undertaken. Lowess lo-
gistic non-parametric. Lowess (non-parametric, locally-
weighted regression analysis), (available in XLSTAT)
[147] was then used to explore predicted, translational
inter-domain relationships for discovered biomarkers
(Figure 2), where ideal significance of predictive probability
is ≥ 60 per cent, for at goodness of fit (R 2) of ≥ 0.6.
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